KR100540463B1 - Composition containing portulaca oleracea L. extract for anti-inflammation and anti-irritation - Google Patents

Composition containing portulaca oleracea L. extract for anti-inflammation and anti-irritation Download PDF

Info

Publication number
KR100540463B1
KR100540463B1 KR1019980049221A KR19980049221A KR100540463B1 KR 100540463 B1 KR100540463 B1 KR 100540463B1 KR 1019980049221 A KR1019980049221 A KR 1019980049221A KR 19980049221 A KR19980049221 A KR 19980049221A KR 100540463 B1 KR100540463 B1 KR 100540463B1
Authority
KR
South Korea
Prior art keywords
extract
inflammation
inflammatory
composition
irritation
Prior art date
Application number
KR1019980049221A
Other languages
Korean (ko)
Other versions
KR20000032674A (en
Inventor
재 찬 양
명 석 윤
동 건 이
Original Assignee
주식회사 엘지생활건강
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 엘지생활건강 filed Critical 주식회사 엘지생활건강
Priority to KR1019980049221A priority Critical patent/KR100540463B1/en
Publication of KR20000032674A publication Critical patent/KR20000032674A/en
Application granted granted Critical
Publication of KR100540463B1 publication Critical patent/KR100540463B1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783Angiosperms [Magnoliophyta]
    • A61K8/9789Magnoliopsida [dicotyledons]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30Extraction of the material
    • A61K2236/33Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/333Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/10General cosmetic use
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74Biological properties of particular ingredients
    • A61K2800/75Anti-irritant

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Chemical & Material Sciences (AREA)
  • Birds (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

본 발명은 오행초 추출물을 함유하는 항염성 및 항자극성 조성물에 관한 것이다. 본 발명의 조성물은 세포독성, 알러지 유발가능성, 염증억제, 피부 1차자극시험등에서 우수한 효과를 나타내고 기존의 항염제에 비해서 피부 안전성 측면에서나 배합시 용해도 및 보존안정성이 탁월하여 적용이 용이하다.The present invention relates to anti-inflammatory and anti-irritant compositions containing pentachopae extract. The composition of the present invention exhibits excellent effects in cytotoxicity, allergic potential, inflammation inhibition, skin primary stimulation test, etc., and is excellent in solubility and preservation stability when combined with conventional anti-inflammatory agents and is easy to apply.

Description

오행초 추출물을 함유하는 항염성 및 항자극성 조성물{Composition containing portulaca oleracea L. extract for anti-inflammation and anti-irritation}Composition containing portulaca oleracea L. extract for anti-inflammation and anti-irritation

본 발명은 항염성 및 항자극성 조성물에 관한 것이다. 좀더 상세하게는 본 발명은 오행초 추출물(portulaca oleracea L. extract)을 함유하여 항염 및 항자극 효과가 뛰어난 조성물에 관한 것이다.The present invention relates to anti-inflammatory and anti-irritant compositions. More specifically, the present invention relates to a composition containing portulaca oleracea L. extract, which has excellent anti-inflammatory and anti-irritant effects.

화장품은 피부를 보호하고 미화 청결을 위해 사용되는 제품이지만 화장품 조성물을 자세하게 살펴보면 본래의 피부 보호 목적과는 상이한 성분들이 제품형성에 필수불가결한 존재이기 때문에 사용된다. 예를들면 가용화제 및 유화제, 방부제, 향료, 자외선차단제 및 기타 효능효과를 부여하기 위해 쓰여지는 여러 가지 부가물을 들 수 있다. 이러한 성분들은 일반적으로 피부에 염증이나, 뾰루지, 부종 등을 유발하는 주원인으로 알려져 있다.Cosmetics are used to protect the skin and to cleanse beautification, but if you look closely at the cosmetic composition is used because different ingredients are indispensable for product formation. Examples include solubilizers and emulsifiers, preservatives, fragrances, sunscreens and other additives used to impart other beneficial effects. These ingredients are generally known to be the main causes of inflammation, rashes and edema in the skin.

염증은 세포나 조직이 어떠한 원인에 의해 손상을 받으면 그 반응을 최소화하고 손상된 부위를 원상으로 회복시키려는 일련의 방어목적으로 나타나는 것이며, 염증을 유발하는 원인으로 외상, 화상, 동상, 방사능 등에 물리적 요인과 산(acid)과 같은 화학물질에 의한 화학적요인 항체반응에 의한 면역학적 요인들이 있으며, 그 외에 혈관이나 호르몬 불균형에 의해서도 일어난다. 염증을 소실시키기 위해 염증원의 제거, 생체반응 및 증상을 감소시키는 작용을 하는 것을 항염제라 한다.Inflammation is a series of defensive purposes intended to minimize the response of a cell or tissue to a damaged body and to restore the damaged area to its original state.Inflammation causes inflammation, burns, frostbite, and radiation. Chemical factors caused by chemicals such as acids There are immunological factors caused by antibody reactions, as well as vascular or hormonal imbalances. Anti-inflammatory drugs are called anti-inflammatory agents that work to eliminate inflammation, reduce bioreactions and symptoms to eliminate inflammation.

화장품에 있어서, 피부 부작용 유발요인은 항상 잠재되어 있으며 이를 해결하고자 여러 가지 연구가 진행되어 왔다. 현재까지 항염의 목적으로 이용되고 있는 물질로는 비스테로이드계로 프루폐나믹산(flufenamic acid), 이부프로펜(ibuprofen), 벤지다민(benzydamine), 인도메타신(indometacine)등이 있고, 스테로이드계통으로 프레드리솔론(prednisolone), 덱사메타손(dexamethasone)등이 있으며(김창종, 병태생리학, 한림상사, p61-69, 1988), 알란토인, 아즈렌, ε-아미노키프론산, 하이드로코티존(v), 감초산 및 그 유도체(β-글리칠레친산, 글리칠레친산유도체)등이 항염증에 효과가 있는 것으로 알려져 있으나(광정무부, 신화장품학, 남산당, p162, 1933), 인도메타신(indometacine)은 화장료에는 사용할 수 없는 물질이고 하이드로코티존은 사용량이 제한되어 있고 감초산 및 그 유도체는 안정화 시키기 어렵거나 용해도가 좋지않아 실제 적용시 농도의 제한으로 인하여 실질적인 효과를 거두기가 어려운 점이 있는등 지금까지 알려진 항염제는 피부안전성 면이나 화장료 배합시의 안정성면에서 대부분 문제점을 가지고 있어서 그 사용이 제한되고 있다. In cosmetics, the cause of skin side effects is always latent and various studies have been conducted to solve this problem. Materials used for anti-inflammatory purposes so far are nonsteroidal flufenamic acid, ibuprofen, benzydamine, indomethacin, and indolecine as steroids. (prednisolone) and dexamethasone (Chang Chang-jong, Pathophysiology, Hallym Co., p61-69, 1988), allantoin, azulene, ε-aminokiproic acid, hydrocortisone (v), licoriceic acid and derivatives thereof β-glycileic acid and glychyl acid derivatives are known to be effective in anti-inflammatory (Ministry of Gwangju, Ministry of Justice, New Cosmetics, Namsan Sugar, p162, 1933), but indometacine cannot be used in cosmetics. Hydrocortisone has a limited amount of usage and licorice acid and its derivatives are difficult to stabilize or have poor solubility. The anti-inflammatory agents known to date have been problematic in terms of skin safety and stability in formulating cosmetics, and their use is limited.

이에 본 발명자는 선행기술의 상술한 문제점을 개선하기 위해 예의 연구한 결과, 오행초추출물을 함유한 의약품이나 화장품 조성물이 피부에 안전성이 우수하며 화장료 배합시 보존안정화가 쉽고 실질적인 효과가 있음을 밝혀내고 본 발명을 완성하였다.Accordingly, the present inventors have diligently researched to improve the above-mentioned problems of the prior art, and found that pharmaceuticals or cosmetic compositions containing the pentacle vinegar extract have excellent safety on the skin and are easy to stabilize and have a substantial effect upon cosmetic formulation. The present invention has been completed.

본 발명은 오행초추출물을 함유하는 항염성 및 항자극성 조성물에 관한 것이다.The present invention relates to anti-inflammatory and anti-irritant compositions containing the pentacle vinegar extract.

오행초는 포장에서 흔히 자라는 육질의 일년생 잡초로서 털이 없고 높이가 30 센티미터에 달하며 갈적색이고 가지가 많이 갈라져서 비스듬히 옆으로 퍼진다. 뿌리는 백색이지만 손으로 벗기면 원줄기와 같이 적색으로 되므로 어린이들이 가지고 장난을 한다. 잎은 대생 또는 호생하지만 끝부분의 것은 수생한 것 같으며 도란형 원두이고 밑부분이 좁아져서 짧은 병엽으로 되며 길이 15∼25밀리미터, 나비 5∼15밀리미터로서 가장자리가 밋밋하다. 꽃은 양성으로서 6월부터 가을까지 계속 피고 황색이며 가지 끝에 달린다. 꽃받침은 2개로서 타원형이고 꽃잎은 5개이며 오므라든다. 수술은 7∼12개, 암술은 1개이고 자방은 중립이며 암술대는 5개이다. 열매는 타원형이고 중앙부가 옆으로 갈라져서 긴 대가 달린 많은 종자가 나온다. 종자는 찌그러진 원형이며 검은 빛이 돌고 가장자리가 약간 토돌토돌하다. 서양에서는 상치와 더불어 사라다를 만들며 우리나라에서는 연한 부분을 나물로하고 전초를 벌레와 뱀의 독을 해소시키거나 또는 질병 및 이뇨제로 사용한다(대한식물도감, 이창복, p324, 1993).The pentagram is a fleshy annual weed that often grows on the pavement, hairless, 30 centimeters high, reddish red, and many branched branches. Roots are white, but when peeled by hand, they become red like a main stem, so children play with them. Leaves are apical or regenerated, but the apex is aquatic, obovate bean, narrowed at the bottom, short lobe, 15-25mm long, 5-15mm butterfly, with flat edges. Flowers are bisexual and continue to bloom from June to autumn, and are yellow and hang on the ends of branches. Calyxes are 2, oval, 5 petals, and shriveled. Surgery is 7-12, pistil is 1, the room is neutral and 5 styles. Fruits are oval, with a central part split to the side, resulting in many seeds with long stems. Seeds are crushed, round, black, slightly rounded at the edges. In the West, salads are made together with lettuce, and in Korea, soft parts are used as herbs, and outposts are used to relieve the poison of insects and snakes, or as diseases and diuretics (Korean Plant Book, Lee Chang-bok, p324, 1993).

오행초추출물은 오행초 1킬로그램을 깨끗이 세척한후 1,3-부틸렌글리콜, 프로필렌글리콜, 에탄올등 통상의 용매로 추출하며, 정제수 2킬로그램과 용매 1킬로그램을 첨가하여 추출한다. The pentacle vinegar extract is washed with one kilogram of pentagonal vinegar and extracted with a common solvent such as 1,3-butylene glycol, propylene glycol, ethanol, and extracted by adding 2 kg of purified water and 1 kg of solvent.

본 발명의 조성물에서 오행초추출물의 함량이 0.001중량부 이하인 경우에는 충분한 효과를 기대할 수 없으며, 30중량부 이상에서는 제품에 배합시 색상 및 냄새, 사용성을 고려할 때 문제점이 발생되었다. 따라서 본 발명의 조성물에서 오행초추출물은 0.001 내지 30.0중량부 함유하는 것이 바람직하다. 본 발명에 따른 조성물은 유연화장수, 영양화장수, 에센스, 영양크림 또는 팩으로 사용될 수 있다.In the composition of the present invention, if the content of the pentagram vinegar extract is 0.001 parts by weight or less can not be expected a sufficient effect, when more than 30 parts by weight when a problem in the color, smell, usability when formulated into the product. Therefore, in the composition of the present invention, it is preferable that the pentaclecho extract contains 0.001 to 30.0 parts by weight. The composition according to the present invention can be used as a softening lotion, nutrient lotion, essence, nutrition cream or pack.

실험 1. 세포독성시험Experiment 1. Cytotoxicity Test

본 발명에서 사용된 오행초 추출물에 대한 세포독성을 알아보기 위하여 V79-4 세포[Chinase Hamster, CCL(continuous cell line:연속세포주)의 폐조직 섬유아세포]를 배양하여 MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide reduction test] 법을 수행하고 MTT-포르마잔 생성물을 이소프로필알코올로 추출하여 570㎚에서 흡광도를 측정하였다. 각각의 물질에 대한 IC50(억제농도 50)을 확인하기 위하여 물질을 배지에 10.0%, 1.0%...로 희석하여 24시간 배양하여 IC50을 구한 결과를 표 1에 나타내었다.In order to investigate the cytotoxicity of the pentacle foliar extract used in the present invention, MTT [3- (4,5] -dimethylthiazol-2-yl) -2,5-diphenyltetrazolium bromide reduction test] was performed and the MTT-formazan product was extracted with isopropyl alcohol to measure absorbance at 570 nm. In order to confirm the IC 50 (inhibition concentration 50) for each substance, the substance was diluted in 10.0%, 1.0% ... in a medium and cultured for 24 hours to obtain an IC 50 .

[표 1]TABLE 1

오행초 추출물의 세포독성 시험결과Cytotoxicity Test Results of Peninsula Extract

오행초 추출물은 소디움라우릴설페이트(SLS)에 비하여 2000배 이상 세포독성이 낮게 나타나 안전성이 우수한 추출물임을 확인하였다.It was confirmed that the five-fold extract was more than 2000-fold lower cytotoxicity compared to sodium lauryl sulfate (SLS).

실험2. 알러지 평가Experiment 2. Allergy assessment

오행초 추출물에 대한 알러지 유발여부를 확인하기 위하여 3일동안 하루 한 번씩 시료를 마우스 귀에 25㎕씩 도포하여 4일째 임파절을 떼어내어 임파구를 분리후 5% 이산화탄소 배양기에서 24 - 48 시간 배양한 후 증폭정도를 방사선 동위원소 [3H]-메칠티미딘(methyl thymidine)의 삽입량으로 측정한다. 국부임파절평가 (LLNA:local lymph node assay)결과는 대조군에 비해 시료군의 임파구 증폭정도로 나타내며 한 농도에서라도 시료의 증폭정도(S.I:stimulation index)가 3배 이상이고 농도별로 증가하는 경향을 보일 경우 알러젠으로 간주하였다.To confirm the allergy to the pentacle fern extract, apply 25µl sample to the mouse ear once a day for 3 days, remove lymph nodes on day 4, isolate lymphocytes, and incubate for 24-48 hours in 5% carbon dioxide incubator. The extent is measured by the intercalation of the radioisotope [ 3 H] -methyl thymidine. The local lymph node assay (LLNA) results indicate the lymphocyte amplification of the sample group compared to the control group, and allergens when the amplification degree (SI) of the sample is more than three times higher than the control group and increase by concentration Considered as.

[표 2]TABLE 2

오행초 추출물의 알러지 평가 결과Allergy Evaluation Results of the Peninsula Extract

※ - cpm(counter per minute) : [3H]-메칠티미딘이 세포 내로 삽입되는 양※ cpm (counter per minute): [ 3 H] -methylthymidine is inserted into the cell

- S.I(stimulation index) : 시료의 평균 cpm을 대조군의 평균 cpm으로 나눈값S.I (stimulation index): The average cpm of the sample divided by the average cpm of the control group.

표 2에서 보는 바와 같이, 오행초 추출물의 증폭정도(S.I)가 3 이하로 알러지 유발 가능성이 거의 없는 것으로 나타났다.As shown in Table 2, it was shown that the amplification degree (S.I) of the pentacle sinensis extract is less than 3, and there is little possibility of allergy.

실험 3. 항염증 실험Experiment 3. Anti-inflammatory Experiment

오행초 추출물에 대한 항염증 효과를 알아보기 위하여 마우스 좌측귀를 대조부위, 우측귀를 시험부위로 하여 시료를 적용전 에탄올로 귀를 깨끗하게 세척하고 시료 20㎕를 1일 1회 4일간 지속적으로 도포하고 마지막 도포 1시간 후에 좌측귀에 에탄올을 우측귀에는 아라키돈산(arachidonic acid)을 2㎎/ear을 도포하여 1시간후 귀의 부종(ear edema)정도를 마이크로미터로 양쪽귀를 3회씩 반복 측정하였다.In order to examine the anti-inflammatory effect on the pentaflora extract, the mouse's left ear was used as the control site and the right ear as the test site. The ears were washed with ethanol before application of the sample, and 20 μl of the sample was continuously applied once a day for 4 days. One hour after the last application, ethanol was applied to the left ear and arachidonic acid (2 mg / ear) was applied to the right ear. After 1 hour, the ear edema was measured three times by micrometer.

항염효과는 아라키돈산(arachidonic acid) 처리군을 기준으로 부종억제 정도로 판정하였다. 그 결과는 표 3에 나타내었다.The anti-inflammatory effect was determined as the degree of edema inhibition based on the arachidonic acid treatment group. The results are shown in Table 3.

[표 3]TABLE 3

국소적용에 의한 귀두께 및 염증억제율Ear thickness and inflammation inhibition rate by topical application

※ 억제율(%)=(A-B)/A x 100※ Inhibition Rate (%) = (A-B) / A x 100

A : 대조군귀의 평균두께(아라키돈산 처리귀의 두께-비처리 귀의 두께)A: Average thickness of control ears (thickness of arachidonic acid treated ears-thickness of untreated ears)

B : 시료도포군 귀의 두께(시료처리귀의 두께-비처리귀의 두께)B: thickness of the sample-coating group ears (thickness of the sample-treated ears-thickness of the untreated ears)

표 3에서 보는바와 같이, 오행초추출물 0.5%, 1.0%, 3.0%는 각각 15.5%, 20.2%, 26.6%의 염증억제율을 보였으며, 부종 증가율로 유의차 검증시 오행초 추출물은 아라키돈산과 99%의 유의수준을 보였다.As shown in Table 3, 0.5%, 1.0%, and 3.0% of the pentacobacterium extract showed 15.5%, 20.2%, and 26.6% of inhibition rate, respectively. The significance level of was shown.

실험 4. 피부 1차 자극성시험(폐쇄첩포실험)Experiment 4. Primary Skin Irritation Test (Closed Wrap Test)

오행초 추출물 1.0%, 3.0% 수용액 및 소디움라우릴설페이트 0.08% 수용액을 건강한 성인 남, 여 50명을 대상으로 등부위에 각 시료의 일정량(0.2g)을 24시간 첩포한후 핀챔버를 제거하고 4시간 경과한 다음 육안으로 피부상태 변화를 판독하였다. 그 결과는 표 4에 나타내었다.A 50% aqueous solution of quincean extract, 3.0% aqueous solution, and 0.08% sodium lauryl sulfate solution were applied to a healthy adult male and female for 24 hours with a certain amount (0.2 g) of each sample on the back, and then the pin chamber was removed. After a lapse of time, the skin condition was read visually. The results are shown in Table 4.

[표 4]TABLE 4

피부 1차 자극성 시험결과Skin primary irritation test result

※ 판정기준 - ; 홍반이나 특이한 현상없음※ Criteria - ; No erythema or unusual symptoms

+- ; 주위보다 약간 붉어짐+-; Slightly redder than the surroundings

+ ; 주위보다 현저히 붉어짐+; Significantly redder than the surroundings

++ ; 주위보다 심하게 붉어지고 부풀어오름++; Severe redness and swelling than the surroundings

이와같이 항염 및 항자극 효과가 우수하며 피부에 안전한 오행초 추출물을 이용하여 다음과 같은 제조예를 실시하였다. In this way, the anti-inflammatory and anti-irritant effect was excellent, and the following preparation examples were performed using the pentacle quince extract safe for the skin.

제조예 1.Preparation Example 1.

제조예 2.Preparation Example 2.

제조예 3.Preparation Example 3.

제조예 4.Preparation Example 4.

제조예 5.Preparation Example 5.

본 발명에 따른 오행초추출물-함유 조성물은 세포독성, 알러지 유발가능성, 염증억제, 피부1차자극시험등에서 우수한 효과를 나타내고, 기존의 항염제에 비해서 피부안전성 측면이나 배합시 용해도 및 보존안정성이 탁월하여 적용이 용이하다. 따라서 본 발명의 조성물은 산업적으로 대단히 유용하다.The pentacle vinegar extract-containing composition according to the present invention exhibits excellent effects in cytotoxicity, allergic potential, inflammation inhibition, skin primary stimulation test, etc., and has superior skin safety and solubility and storage stability when combined with conventional anti-inflammatory agents. Easy to apply Therefore, the composition of the present invention is very useful industrially.

Claims (3)

오행초 추출물을 함유함을 특징으로 하는 항염 또는 항자극 효과를 갖는 피부 외용제 조성물.A composition for external application for skin having an anti-inflammatory or anti-irritant effect, which contains a pentachopa extract. 제 1항에 있어서, 오행초 추출물을 0.001∼30.0 중량부 함유함을 특징으로 하는 조성물. The composition of claim 1, wherein the composition contains 0.001 to 30.0 parts by weight of the pentacle fern extract. 제 1항에 있어서, 유연화장수, 영양화장수, 에센스, 영양크림 또는 팩인 조성물.The composition according to claim 1, which is softening cream, nutrient cream, essence, nourishing cream or pack.
KR1019980049221A 1998-11-17 1998-11-17 Composition containing portulaca oleracea L. extract for anti-inflammation and anti-irritation KR100540463B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1019980049221A KR100540463B1 (en) 1998-11-17 1998-11-17 Composition containing portulaca oleracea L. extract for anti-inflammation and anti-irritation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1019980049221A KR100540463B1 (en) 1998-11-17 1998-11-17 Composition containing portulaca oleracea L. extract for anti-inflammation and anti-irritation

Publications (2)

Publication Number Publication Date
KR20000032674A KR20000032674A (en) 2000-06-15
KR100540463B1 true KR100540463B1 (en) 2006-04-20

Family

ID=19558609

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019980049221A KR100540463B1 (en) 1998-11-17 1998-11-17 Composition containing portulaca oleracea L. extract for anti-inflammation and anti-irritation

Country Status (1)

Country Link
KR (1) KR100540463B1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100535264B1 (en) * 1998-12-30 2006-03-23 주식회사 엘지생활건강 Skin whitening composition containing pentachoea extract
KR20020016960A (en) * 2000-08-28 2002-03-07 유상옥,송운한 Skin Care Composition Containing Portulaca Extract
ES2416804B1 (en) * 2011-12-28 2014-06-04 Roberto TUDINI Composition of natural products for topical application
CN108084060B (en) * 2017-12-07 2020-04-21 辽宁中医药大学 Alkaloid oleraurea in purslane and extraction and separation method thereof

Also Published As

Publication number Publication date
KR20000032674A (en) 2000-06-15

Similar Documents

Publication Publication Date Title
US5503825A (en) Lip balm composition
JPH07278003A (en) Testosterone-5alpha-reductase inhibitor
JPH08119825A (en) Hydroxytyrosol, application for skin external medicine or bathing agent
JPH0587482B2 (en)
JP3407935B2 (en) External preparation for skin
JPH1045615A (en) Plant extract-containing fibroblast growth promoter
KR101230277B1 (en) Composition of External Application for Using Bamboo Sprout
JPH09301821A (en) Lipase activity promoter
US20040126351A1 (en) Topical composition having natural skin anti-irritant ingredient and method of use
KR101732906B1 (en) Skin care and atopic dermatitis cosmetic compositions containing asiatic pennywort extract, magnolia bark extract, hiba arborvitae branch extract, eucalyptus oil and borage seed oil
JPH10203955A (en) Antimicrobial low-irritating cosmetic
KR100561780B1 (en) Cosmetic compositions for anti-irritation containing ponciri fructus extracts as effective ingredients
JPH09227353A (en) Skin whitening cosmetic composition
KR100540463B1 (en) Composition containing portulaca oleracea L. extract for anti-inflammation and anti-irritation
JP2002316937A (en) Plant extract-containing anti-allergic agent
KR20020001911A (en) Cosmetic composition containing portulaca oleracea L. extract for anti-inflammation and anti-irritation
KR102445830B1 (en) Cosmetic Compositions for Skin Moisture Comprising Extract of Triticum aestivum
KR101127393B1 (en) Composition for preventing or alleviating atopic dermatitis, and process for preparing the same
KR101233944B1 (en) Composition for Preventing Hair Loss or Promoting Hair Generation
JPH10279428A (en) Cosmetic
KR101134790B1 (en) Composition for improving acne skin containing Hinokitiol and Ampelopsis radix extract
JPH03112912A (en) Cosmetic composition
JPH0525849B2 (en)
JPH04124138A (en) External preparation for skin
KR100954984B1 (en) Anti-inflammatory cosmetic compositions containing of herb medicines

Legal Events

Date Code Title Description
N231 Notification of change of applicant
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20120914

Year of fee payment: 8

FPAY Annual fee payment

Payment date: 20130913

Year of fee payment: 9

FPAY Annual fee payment

Payment date: 20140917

Year of fee payment: 10

FPAY Annual fee payment

Payment date: 20150917

Year of fee payment: 11

FPAY Annual fee payment

Payment date: 20160919

Year of fee payment: 12

FPAY Annual fee payment

Payment date: 20170928

Year of fee payment: 13